Lilly Drug to Change Squamous NSCLC, but ODAC's Opinion is Nuanced

By Paul Goldberg

The FDA Oncologic Drugs Advisory Committee July 9 appears to have recommended approval for the Eli Lilly and Co. agent necitumumab.Yes, the word “appears” has indeed appeared in the previous sentence.

Do-It-Yourself Guide to ODAC Circle One: Yes, No, Maybe

Huntsman, UNM, and UT Southwestern Receive NCI Comprehensive Designations

ORIEN Partners with Three Cancer Research Centers

Recent Issues

Volume 51 | Issue 07 - February 21, 2025

Scroll to top

Lilly Drug to Change Squamous NSCLC, but ODAC's Opinion is Nuanced

Do-It-Yourself Guide to ODAC Circle One: Yes, No, Maybe

Huntsman, UNM, and UT Southwestern Receive NCI Comprehensive Designations

ORIEN Partners with Three Cancer Research Centers

In Brief

Britten Named Hematology/Oncology Director at Medical University of South Carolina

Marcia McNutt nominated to be president of the National Academy of Sciences

Kevin Fitzpatrick named CEO of CancerLinQ LLC

Memorial Sloan Kettering Cancer Center to open new lung cancer research center

American College of Radiology launches Commission on Patient Experience

The Association of Community Cancer Centers launches the Institute for Clinical Immuno-Oncology

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login